TerminatedNot Applicable

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

Stopped: recruitment not met

United States6 participantsStarted 2011-08

Plain-language summary

The purpose of this study is to evaluate the effect of dexamethasone intravitreal implant (Ozurdex) in combination with pars plana vitrectomy and membrane peeling for idiopathic epiretinal membrane (ERM).

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with idiopathic epiretinal membrane * Preoperative visual acuity of snellen equivalent 20/32 or worse Exclusion Criteria: * History or presence of any of the following: * uveitis * macular hole * previous vitreoretinal surgery * any other retinal pathology that could affect anatomic or functional results * Age Related Macular Degeneration * Diabetic Retinopathy * Diabetic Macular Edema * Retinal Vein Occlusion * Pre-existing Macular Disease

What they're measuring

Changes in best corrected visual acuity

Timeframe: 6 months

Trial details

NCT IDNCT01410201

SponsorBarnes Retina Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-01

View on ClinicalTrials.gov More Epiretinal Membrane trials